PRESS RELEASE published on 03/18/2026 at 07:00, 7 months 19 days ago Blue Cap AG publishes preliminary financial figures for 2025: successful financial year 2025 Blue Cap AG reports successful financial year 2025 with EUR 129.1 million revenue and 5.5% adjusted EBITDA margin. Focus on Industrials and Business Services segments. Forecast for 2026 remains stable Financial Results Revenue EBITDA Margin Blue Cap AG Forecast
PRESS RELEASE published on 03/18/2026 at 07:00, 7 months 19 days ago Newron announces nominations to its Board of Directors at upcoming Annual General Meeting Newron Pharmaceuticals S.p.A. announces nominations for new Board members and resignations of current members ahead of its Annual General Meeting. Full agenda to be released on March 24, 2026 Board Of Directors Annual General Meeting Nominations Newron Pharmaceuticals Resignations
REGULATED PRESS RELEASE published on 03/18/2026 at 07:00, 7 months 19 days ago Mersen: A resilient performance in 2025, return to growth expected in 2026 Mersen demonstrates resilient performance in 2025 with sales of €1,186 million and 2026 guidance for organic sales growth between 2% and 6%. Return to positive free cash flow ahead of schedule Mersen Sales Growth Free Cash Flow Resilient Performance 2026 Guidance
PRESS RELEASE published on 03/18/2026 at 07:00, 7 months 19 days ago 2025 annual results: strong improvement in financial earnings and cash-flows Exail Technologies achieved significant financial growth in 2025 with record order intake of €844 million (+87%), revenue growth of +28%, and strengthened balance sheet post fundraising of €300 million. Operational milestones include delivering mine countermeasures to navies and increasing production capacity for navigation systems Financial Growth Record Order Intake Exail Technologies Operational Milestones Strengthened Balance Sheet
PRESS RELEASE published on 03/18/2026 at 07:00, 7 months 19 days ago Press Release: Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Sanofi's venglustat receives Breakthrough Therapy designation in the US for type 3 Gaucher disease, a rare lysosomal storage disorder. Positive results from the LEAP2MONO study show significant improvements in neurological symptoms Sanofi Breakthrough Therapy Venglustat Gaucher Disease Neurological Symptoms
PRESS RELEASE published on 03/18/2026 at 06:55, 7 months 19 days ago Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China Heidelberg Pharma to receive milestone payment from partner Huadong for clinical study with HDP-101 in China. First patient dosed in Phase I study evaluating safety, tolerability, and efficacy China Clinical Study Heidelberg Pharma HDP-101 Milestone Payment
PRESS RELEASE published on 03/18/2026 at 06:55, 7 months 19 days ago SMG reports strong 2025 results with significant margin uplift SMG Swiss Marketplace Group reports strong 2025 financial results with revenue of CHF 332.0 million and Adjusted EBITDA up to CHF 180.2 million, lifting margin to 54.3%. Continues innovating with AI for user experience and efficiency Adjusted EBITDA AI Innovation Revenue Growth 2025 Financial Results SMG Swiss Marketplace Group
PRESS RELEASE published on 03/18/2026 at 06:55, 7 months 19 days ago TAG Immobilien AG exceeds guidance for the 2025 financial year TAG Immobilien AG exceeds guidance for the 2025 financial year, reporting strong financial performance and growth in Germany and Poland. Acquisitions and decarbonisation strategy milestones achieved Acquisitions Germany TAG Immobilien AG Poland 2025 Financial Year
PRESS RELEASE published on 03/18/2026 at 06:30, 7 months 19 days ago The 2025 annual results reflect developments in the companies and investments under the umbrella of TX Group AG TX Group AG's 2025 annual results show positive developments in marketplace activities and media companies' transformation. Revenue slightly down, operational income stable Media Companies Operating Income 2025 Annual Results TX Group AG Marketplace Activities
PRESS RELEASE published on 03/18/2026 at 06:30, 7 months 19 days ago Orell Füssli AG: Orell Füssli reports successful financial year 2025 Orell Füssli AG reports successful financial year 2025 with revenue up by 8% and net profit rising by 31%. Dividend proposal of CHF 5.80 per share. Strategic targets for 2028 raised Revenue Growth Dividend Proposal Strategic Targets Financial Year 2025 Orell Füssli AG
Published on 11/06/2026 at 13:00, 4 hours 57 minutes ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 5 hours 27 minutes ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 5 hours 27 minutes ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 05:15, 12 hours 42 minutes ago Valeo and QNX Unveil A New Smart Camera Platform at CIIE, Secures Multiple Design Wins
Published on 11/06/2026 at 17:41, 15 minutes ago Turkiye Garanti Bankasi A.S.: Daily Share Buyback Transactions
Published on 11/06/2026 at 14:50, 3 hours 6 minutes ago New UN guide keeps people in charge of AI in smart cities
Published on 11/06/2026 at 14:45, 3 hours 11 minutes ago Ningbo Consensus on Collaborative Development released at 2026 Global Mayors Dialogue · Ningbo
Published on 11/06/2026 at 17:54, 2 minutes ago Disclosure of Share Capital and Voting Rights as of October 31, 2026
Published on 11/06/2026 at 17:35, 22 minutes ago Disclosure of the number of shares and the total number of voting rights as of October 31, 2026
Published on 11/05/2026 at 18:21, 23 hours 35 minutes ago Total number of voting rights and shares making up the share capital at October 31, 2026